Biosimilar Market in Europe Industry Growth, Trends, Share, Size, Opportunity and Forecast 2018-2023

1

Biosimilar Market in Europe Driven by Ongoing
Awareness Initiatives
Copyright IMARC. All Rights Reserved
2
About IMARC Group
Report Description
IMARC is a leading advisor on management
strategy and market research worldwide. We
partner with clients in all sectors and regions
to identify their highest-value opportunities,
address their most critical challenges, and
transform their businesses. IMARCs information
products include major market, scientific,
economic and technological developments for
business leaders in pharmaceutical, industrial,
and high technology organizations. Market
forecasts and industry analysis for
biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and
tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Biosimilar Market in Europe Driven by Ongoing
Awareness Initiatives Owing to the changing
perception towards biosimilars and favorable
guidelines laid down by the European Medicines
Agency (EMA), the biosimilar market in Europe has
witnessed a robust growth over the past several
years. IMARC Groups latest report, entitled
Biosimilar Market in Europe Industry Trends,
Share, Size, Growth, Opportunity and Forecast
2018-2023, finds that the biosimilar market in
Europe reached a value of US 2,013 Million in
2017. Biosimilars refer to biological drugs which
are highly similar to already approved branded
drugs in terms of safety, efficacy, structure,
immunogenicity profile, etc. In Europe,
biosimilars are manufactured, developed and
approved according to the stringent laws laid
down by the European Medicines Agency (EMA). A
significant rise in the ageing population has led
to the prevalence of various chronic diseases in
the region. For instance, according to a report
by WHO, cancer has emerged as the second major
cause of death and morbidity in Europe with more
than 3.7 million new cases and 1.9 million deaths
each year. As a result of this, cancer supportive
biosimilars, such as Filgrastim and
Erythropoietin, are widely being recommended by
doctors in the region. Moreover, the biosimilar
manufacturers in the region are continuously
developing new products which are projected to
help in increasing the availability of biological
treatments for the patients.
4
Report Description and Highlights
Report Description

• European Biosimilar Market Trends
• The growing awareness among the patients in
  Europe regarding the efficacy and safety of
  biosimilars as compared to patented drugs has
  created a positive outlook for the market growth.
  Apart from this, as patients have limited access
  to biologics owing to their relatively high cost,
  there has been a huge demand for the lower priced
  biosimilars. This has further helped in lowering
  the cost of treatment of chronic diseases such as
  diabetes, cancer, CVDs, autoimmune diseases,
  rheumatoid arthritis, kidney failure, growth
  hormone deficiency, infectious diseases, etc.
  Moreover, the EMA and the European Commission are
  working towards improving the understanding of
  biosimilar use across the European Union (EU). In
  line with this, they have published information
  material on biosimilar medicines which offers
  healthcare professionals with comprehensive
  information about their regulations and usage. As
  a result of these factors, the market is
  projected to exceed a value of US 9,173 Million
  by 2023, exhibiting at a CAGR of 29 during
  2017-2023.
• European Biosimilar Market Summary
• Based on molecule, infliximab dominates the
  market, accounting for the highest sales. Other
  major molecules include insulin glargine, epoetin
  alfa, etanercept, filgrastim, somatropin,
  rituximab and follitropin alfa.

5
Report Description and Highlights
Report Description

• Read more here http//bit.ly/2yHrbqR
• On the basis of manufacturing type, the market
  has been segmented into in-house and contract
  manufacturing. Currently, in-house manufacturing
  represents the largest segment, holding the
  majority of the overall market share.
• Based on indication, autoimmune diseases are the
  biggest indication for biosimilars. Other major
  indications include oncology, autoimmune
  diseases, blood disorders, growth deficiency and
  diabetes.
• Region-wise, Italy enjoys the leading position in
  the European biosimilar market. Cost containment
  measures in the country represent the major
  driver catalyzing the uptake of biosimilars in
  the country. Other major markets are Germany, the
  United Kingdom, France, and Spain.
• The competitive landscape of the biosimilar
  market in Europe has also been analyzed with some
  of the key players being Novartis, Pfizer, Teva,
  Ratiopharm, Celltrion, Merck Sharp Dohme,
  Samsung Bioepis, Eli Lilly, Accord Healthcare
  Ltd., Mylan, Boehringer Ingelheim, Hexal Ag,
  Apotex, Stada Arzneimittel Ag, and Amgen.
• Want more information about this market? Request
  a free report sample
• https//www.imarcgroup.com/request?typereportid
  1023flagB

6
Report Description and Highlights
Browse More Related Reports  Biosimilar
Market http//bit.ly/2RPDZ7n Intrauterine
Devices Market  http//bit.ly/2RF4iwY
7
Report Description and Highlights
Report Description

2017 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
8

Contact Us